Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study.
Andrea ForschnerStephanie WeißgraeberDirk HadaschikMartin SchulzeMaria KoppSabine KelkenbergTobias SinnbergClaus GarbeSaskia BiskupFlorian BattkePublished in: OncoTargets and therapy (2020)
Therapy monitoring by ctDNA seems to be a reliable method for detecting extracranial progression, even more sensitive and specific than LDH or S100B. However, due to the small number of cases in our study, further studies are necessary.